AbbVie Inc.
General ticker "ABBV" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $378.9B (TTM average)
AbbVie Inc. follows the US Stock Market performance with the rate: 23.0%.
Estimated limits based on current volatility of 1.1%: low 255.07$, high 260.80$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-07-15, amount 1.73$ (Y2.70%)
- Total employees count: 57000 as of 2025
- US accounted for 76.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Patent expiration, R&D failure, Pricing pressure, Manufacturing risks, Supply chain disruptions
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [203.91$, 287.28$]
- 2026-12-31 to 2027-12-31 estimated range: [220.36$, 308.43$]
Financial Metrics affecting the ABBV estimates:
- Positive: with PPE of 22.9 at the end of fiscal year the price was neutral
- Positive: 22.58 < Operating profit margin, % of 24.55
- Positive: 2.37 < Operating cash flow per share per price, % of 4.68
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 3.06
- Positive: Industry inventory ratio change (median), % of 0.50 <= 1.15
- Positive: 5.56 < Industry operating cash flow per share per price (median), % of 5.61
- Positive: Industry earnings per price (median), % of 6.62 > 6.58
- Positive: Inventory ratio change, % of 0.55 <= 1.34
- Positive: 14.78 < Industry operating profit margin (median), % of 24.67
Short-term ABBV quotes
Relationship graph
Long-term ABBV plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $54,497.00MM | $56,341.00MM | $61,401.00MM |
| Operating Expenses | $41,740.00MM | $47,204.00MM | $46,326.00MM |
| Operating Income | $12,757.00MM | $9,137.00MM | $15,075.00MM |
| Non-Operating Income | $-6,507.00MM | $-5,421.00MM | $-8,478.00MM |
| Interest Expense | $1,684.00MM | $2,160.00MM | $2,627.00MM |
| R&D Expense | $7,675.00MM | $12,791.00MM | $9,096.00MM |
| Income(Loss) | $6,250.00MM | $3,716.00MM | $6,597.00MM |
| Taxes | $1,377.00MM | $-570.00MM | $2,364.00MM |
| Net Income(Loss)* | $4,820.00MM | $4,278.00MM | $4,226.00MM |
| Stockholders Equity | $10,360.00MM | $3,325.00MM | $-3,270.00MM |
| Inventory | $4,099.00MM | $4,181.00MM | $4,951.00MM |
| Assets | $134,711.00MM | $135,161.00MM | $133,960.00MM |
| Operating Cash Flow | $22,839.00MM | $18,806.00MM | $19,030.00MM |
| Capital expenditure | $777.00MM | $974.00MM | $1,214.00MM |
| Investing Cash Flow | $-2,009.00MM | $-20,820.00MM | $-6,643.00MM |
| Financing Cash Flow | $-17,222.00MM | $-5,211.00MM | $-12,724.00MM |
| Earnings Per Share** | $2.73 | $2.42 | $2.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.